Goldman Sachs starts coverage on ResMed with "buy" rating

Investing.com

01-17

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Key drivers include rising awareness of obstructive sleep apnea (OSA), market share gains in OSA masks, and operating margin expansion through cost management and product mix. Goldman forecasts mask revenue growth exceeding consensus by 2.4%-10.7% for fiscal 2025-27.

The note highlights ResMed's ongoing innovation, with new mask and accessory launches expected in late 2024, and predicts the company could achieve the upper end of its fiscal 2030 revenue growth target.

Goldman believes CPAP therapy will coexist with GLP-1 drugs for OSA treatment, supported by clinical data and insurance policies. ResMed's app engagement also indicates strong therapy compliance.

The 12-month price target reflects a 30% upside, based on a blend of discounted cash flow and EV/EBIT multiples.

Related Articles

Goldman Sachs starts coverage on ResMed with "buy" rating

Building permits, housing starts data due Friday

State Street, Schlumberger, Regions lead Friday earnings lineup

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2504415799"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2504415799\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2504415799?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-17 03:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504415799","market":"us","top_or_hot":-1,"title":"Goldman Sachs starts coverage on ResMed with \"buy\" rating","media":"Investing.com","content":"<html><body><p>Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a \"Buy\" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.</p>\n<p>Key drivers include rising awareness of obstructive sleep apnea (OSA), market share gains in OSA masks, and operating margin expansion through cost management and product mix. Goldman forecasts mask revenue growth exceeding consensus by 2.4%-10.7% for fiscal 2025-27.</p>\n<p>The note highlights ResMed's ongoing innovation, with new mask and accessory launches expected in late 2024, and predicts the company could achieve the upper end of its fiscal 2030 revenue growth target.</p>\n<p>Goldman believes CPAP therapy will coexist with GLP-1 drugs for OSA treatment, supported by clinical data and insurance policies. ResMed's app engagement also indicates strong therapy compliance.</p>\n<p>The 12-month price target reflects a 30% upside, based on a blend of discounted cash flow and EV/EBIT multiples.</p>\n<p>Related Articles</p>\n<p>Goldman Sachs starts coverage on ResMed with \"buy\" rating</p>\n<p>Building permits, housing starts data due Friday</p>\n<p>State Street, Schlumberger, Regions lead Friday earnings lineup</p>\n</body></html>","source":"yahoofinance_au","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs starts coverage on ResMed with \"buy\" rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs starts coverage on ResMed with \"buy\" rating\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Investing.com</strong><span class=\"h-time small\">2025-01-17 03:01</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a \"Buy\" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.</p>\n<p>Key drivers include rising awareness of obstructive sleep apnea (OSA), market share gains in OSA masks, and operating margin expansion through cost management and product mix. Goldman forecasts mask revenue growth exceeding consensus by 2.4%-10.7% for fiscal 2025-27.</p>\n<p>The note highlights ResMed's ongoing innovation, with new mask and accessory launches expected in late 2024, and predicts the company could achieve the upper end of its fiscal 2030 revenue growth target.</p>\n<p>Goldman believes CPAP therapy will coexist with GLP-1 drugs for OSA treatment, supported by clinical data and insurance policies. ResMed's app engagement also indicates strong therapy compliance.</p>\n<p>The 12-month price target reflects a 30% upside, based on a blend of discounted cash flow and EV/EBIT multiples.</p>\n<p>Related Articles</p>\n<p>Goldman Sachs starts coverage on ResMed with \"buy\" rating</p>\n<p>Building permits, housing starts data due Friday</p>\n<p>State Street, Schlumberger, Regions lead Friday earnings lineup</p>\n</body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/goldman-sachs-starts-coverage-resmed-190132176.html\">Investing.com</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD","symbol_name":"瑞思邁","start_time":0,"source_url":"https://finance.yahoo.com/news/goldman-sachs-starts-coverage-resmed-190132176.html","article_id":"2504415799","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504415799","pubTimestamp":1737054092,"columns":[],"sourceInfo":{"source_id":"yahoofinance_au","name":"Yahoo Finance AU"},"weMediaInfo":null,"summary":"Investing.com --Goldman Sachs initiated coverage on ResMed Inc  with a \"Buy\" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure  therapy segment.Key drivers include rising awareness of obstructive sleep apnea , market share gains in OSA masks, and operating margin expansion through cost management and product mix. Goldman forecasts mask revenue growth exceeding consensus by 2.4%-10.7% for fiscal 2025-27.The note highlights ResMed's ongoing innovation, with new mask and accessory launches expected in late 2024, and predicts the company could achieve the upper end of its fiscal 2030 revenue growth target.Goldman believes CPAP therapy will coexist with GLP-1 drugs for OSA treatment, supported by clinical data and insurance policies. ResMed's app engagement also indicates strong therapy compliance.The 12-month price target reflects a 30% upside, based on a blend of discounted cash flow and EV/EBIT multiples.State Street, Schlumberger, R","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"RMD":"瑞思迈","RMD.AU":"Resmed DRC"},"translate_title":"高盛开始对瑞思迈给予“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a \"Buy\" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.\nKey drivers include rising awareness of obstructive sleep apnea (OSA), market share gains in OSA masks, and operating margin expansion through cost management and product mix. Goldman forecasts mask revenue growth exceeding consensus by 2.4%-10.7% for fiscal 2025-27.\nThe note highlights ResMed's ongoing innovation, with new mask and accessory launches expected in late 2024, and predicts the company could achieve the upper end of its fiscal 2030 revenue growth target.\nGoldman believes CPAP therapy will coexist with GLP-1 drugs for OSA treatment, supported by clinical data and insurance policies. ResMed's app engagement also indicates strong therapy compliance.\nThe 12-month price target reflects a 30% upside, based on a blend of discounted cash flow and EV/EBIT multiples.\nRelated Articles\nGoldman Sachs starts coverage on ResMed with \"buy\" rating\nBuilding permits, housing starts data due Friday\nState Street, Schlumberger, Regions lead Friday earnings lineup","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}